摘要
目的探讨WT1基因在多发性骨髓瘤(MM)中的表达情况及临床意义。方法用RT-PCR检测25例MM患者和10例正常对照骨髓或外周血细胞的WT1基因的表达情况,用Tanon GIS2010系统分析PCR产物,并对其表达量进行统计学分析。结果 10例正常对照骨髓或外周血未检出WT1基因表达,25例MM中WT1的阳性率为36%,按Durie-Salmon分期后,其中Ⅰ期阳性率为0,Ⅱ期阳性率为24%,Ⅲ期阳性率为63.64%,治疗无效组中的阳性率为57.14%,WT1基因表达在MM的DS分期中呈现明显的阶段性。WT1基因的相对表达量与β2-微球蛋白水平分别在MM的DS分期中每两组进行比较均有统计学意义(P<0.05),经相关性分析MM患者WT1基因相对表达量与β2-微球蛋白水平呈正相关,且均与分期进展有关。动态观察2例MM的Ⅲ期患者,WT1基因与患者的分期不良预后有关。结论WT1基因可以作为MM的另一个评估指标,预测病情进展及预后。
Objective To explore the expression and clinical significance of WT1 gene in multiple myeloma（MM）. Methods The expression of WT1 gene was measured in the peripheral blood cells or bone marrow cells, of 25 patients with multiple myeloma and 10 normal controls by reverse transcdptase polymerase chain reaction （RT-PCR） method. Results WT1 gene was not detected in 10 normal controls. The positive expression rate of the WT1 gene in 25 patients was 36%. According to Durie-Salmon stage, WT1 gene was not detected in these patients with MM who was in the first phase of Dune-Salmon stage. But the expression of WT1 gene was higher in these patients of the second and third stage. The positive rates were 24%, 63.64%, respectively. The positive rate of the expression of WT1 gene with ineffective treatment patients was 57.14%, the expression of WT1 gene in MM presented obvious stage by Durie-Salmon stage. The relative quantity of WT1 gene and the level of β2-microglobulin in Durie-Salmon stage of MM patients all had statistical significance compared between every two group （P 〈 0. 05）. They had a positive relationship between WT1 gene and the level of β2-microglobulin by correlation analysis, and related to the Dude-Salmon stage. The poor prognosis of patients wasassociated with the expression of WT1 gene after dynamic observation in 2 cases of patients with MM m period. Conclusion The expression of WT1 gene could be an additional marker in risk assessment for MM.
出处
《哈尔滨医科大学学报》
CAS
北大核心
2012年第6期576-578,共3页
Journal of Harbin Medical University
